Telomeres, Aging and Neurodegenerative Diseases: Molecular Mechanisms, Clinical Evidence and Therapeutic Perspectives
- 1OASI Research Institute—IRCCS, Neuropharmacology Section, 94018 Troina, Italy
Abstract
Telomeres are regions located at the ends of chromosomes, consisting of tandemly repeated nucleotide sequences. Their primary functions are to protect chromosome ends, prevent the recognition of natural chromosome termini as DNA double-strand breaks and contribute to the regulation of cellular replicative capacity. Indeed, with each cell division cycle, they shorten until reaching a critical threshold that signals the cell to stop replicating, a process known as “cellular senescence”. Telomere shortening also occurs in response to oxidative stress and DNA damage; several studies have reported an association between shorter telomere length and neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), and dementia-related outcomes. However, findings are heterogeneous, and the relationship between telomere length and cognitive or functional decline remains incompletely understood. Telomere dysfunction may also affect glial cell function, potentially contributing to chronic neuroinflammation and the release of pro-inflammatory molecules. This process increases neuronal vulnerability. Several studies suggest that telomere damage may influence the neurotoxicity caused by β-amyloid oligomers and accelerate neurodegenerative processes. Furthermore, in experimental models, interventions targeting telomerase, the enzyme that preserves DNA integrity by lengthening lost telomere repeats, have shown potential therapeutic promise. However, the relationship between telomere shortening and disease progression is still unclear, and telomere length cannot even be considered a clinically applicable predictive biomarker. Although telomere shortening is a marker of biological aging and a potential factor in the pathogenesis of neurodegenerative diseases, large-scale longitudinal studies and interventional trials are needed to consider telomeres as biomarkers and therapeutic targets for neurodegenerative diseases.
Related
- AAV9 Gene Therapy for Ovarian Dysfunction and Reproductive Aging: Molecular Mechanisms, Therapeutic Targets, and Translational Perspectives
- Mitochondrial Dysfunction in Neurodegenerative Diseases: Molecular Mechanisms, Primary Drivers Versus Early Amplifiers, and Emerging Mitochondria-Targeted Therapeutic Strategies
- Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives
- Microbiota Dysbiosis and the Gut-Brain Axis in Psychiatric Disorders: Molecular Mechanisms, Clinical Evidence, and Therapeutic Perspectives
- Functional Autoantibodies Against G-Protein-Coupled Receptors: Insights into Molecular Mechanisms, Clinical Relevance and Therapeutic Perspectives
BibTeX
@article{grasso2026telomeres,
title = {{Telomeres, Aging and Neurodegenerative Diseases: Molecular Mechanisms, Clinical Evidence and Therapeutic Perspectives}},
author = {Margherita Grasso and Chiara Mascali and Francesca L’Episcopo},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210228},
url = {https://www.mdpi.com/1422-0067/27/22/10228},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Telomeres, Aging and Neurodegenerative Diseases: Molecular Mechanisms, Clinical Evidence and Therapeutic Perspectives
AU - Margherita Grasso
AU - Chiara Mascali
AU - Francesca L’Episcopo
PY - 2026
DA - 2026/11/14
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210228
UR - https://www.mdpi.com/1422-0067/27/22/10228
AB - Telomeres are regions located at the ends of chromosomes, consisting of tandemly repeated nucleotide sequences. Their primary functions are to protect chromosome ends, prevent the recognition of natural chromosome termini as DNA double-strand breaks and contribute to the regulation of cellular replicative capacity. Indeed, with each cell division cycle, they shorten until reaching a critical threshold that signals the cell to stop replicating, a process known as “cellular senescence”. Telomere shortening also occurs in response to oxidative stress and DNA damage; several studies have reported an association between shorter telomere length and neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), and dementia-related outcomes. However, findings are heterogeneous, and the relationship between telomere length and cognitive or functional decline remains incompletely understood. Telomere dysfunction may also affect glial cell function, potentially contributing to chronic neuroinflammation and the release of pro-inflammatory molecules. This process increases neuronal vulnerability. Several studies suggest that telomere damage may influence the neurotoxicity caused by β-amyloid oligomers and accelerate neurodegenerative processes. Furthermore, in experimental models, interventions targeting telomerase, the enzyme that preserves DNA integrity by lengthening lost telomere repeats, have shown potential therapeutic promise. However, the relationship between telomere shortening and disease progression is still unclear, and telomere length cannot even be considered a clinically applicable predictive biomarker. Although telomere shortening is a marker of biological aging and a potential factor in the pathogenesis of neurodegenerative diseases, large-scale longitudinal studies and interventional trials are needed to consider telomeres as biomarkers and therapeutic targets for neurodegenerative diseases.
SN - 1422-0067
ER -